Your browser doesn't support javascript.
loading
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Cremolini, Chiara; Marmorino, Federica; Bergamo, Francesca; Aprile, Giuseppe; Salvatore, Lisa; Masi, Gianluca; Dell'Aquila, Emanuela; Antoniotti, Carlotta; Murgioni, Sabina; Allegrini, Giacomo; Borelli, Beatrice; Gemma, Donatello; Casagrande, Mariaelena; Granetto, Cristina; Delfanti, Sara; Di Donato, Samantha; Schirripa, Marta; Sensi, Elisa; Tonini, Giuseppe; Lonardi, Sara; Fontanini, Gabriella; Boni, Luca; Falcone, Alfredo.
Afiliação
  • Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Marmorino F; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Bergamo F; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology - IRCCS, Padova, Italy.
  • Aprile G; Department of Oncology, University and General Hospital, Udine, Italy; Department of Oncology, General Hospital, ULSS8 Berica - East District, 36100, Vicenza, Italy.
  • Salvatore L; U.O.C Oncologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Roma, Italy.
  • Masi G; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Dell'Aquila E; Department of Medical Oncology, University Campus Biomedico, Rome, Italy.
  • Antoniotti C; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Murgioni S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology - IRCCS, Padova, Italy.
  • Allegrini G; Unit of Medical Oncology, Livorno Hospital, Department of Medical Oncology, Azienda Toscana Nord Ovest, Livorno, Italy.
  • Borelli B; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Gemma D; Department of Medical Oncology, Hospital of Frosinone, Frosinone, Italy.
  • Casagrande M; Department of Oncology, University and General Hospital, Udine, Italy.
  • Granetto C; Department of Oncology, S. Croce and Carle Teaching Hospital, Cuneo, Italy.
  • Delfanti S; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Di Donato S; Medical Oncology Department, Nuovo Ospedale-Santo Stefano, Prato, Italy.
  • Schirripa M; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology - IRCCS, P
  • Sensi E; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
  • Tonini G; Department of Medical Oncology, University Campus Biomedico, Rome, Italy.
  • Lonardi S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology - IRCCS, Padova, Italy.
  • Fontanini G; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
  • Boni L; Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Florence, Italy.
  • Falcone A; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address: alfredo.falcone@med.unipi.it.
Eur J Cancer ; 109: 175-182, 2019 03.
Article em En | MEDLINE | ID: mdl-30735919
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Colon_e_reto Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Colon_e_reto Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália